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Aims To investigate the role of guidelines in structuring the clinical care for adult patients with conge-
nital heart disease (CHD), and to assess adherence to the guidelines in Europe.
Methods and results A selected number of current guidelines were chosen pertaining to operative pro-
cedures, investigations, and the use of medication (‘interventions’). The source for this analysis was the
database of the Euro Heart Survey on adult CHD, which contains retrospectively collected data on 4110
patients followed-up for a median of 5.1 years. For each guideline investigated, patients were selected
from the database for whom the particular guideline was relevant. The selected cases were classiﬁed
according to two criteria: was there an indication for the particular intervention and did the interven-
tion take place? In this manner, cases of ‘undue treatment’ and ‘insufﬁcient treatment’ were identiﬁed.
Adherence to guidelines was found to be good in the case of operative procedures and prophylactic drug
treatment. However, regarding diagnostic procedures there had been adherence to guidelines in only
slightly more than half of the cases.
Conclusion Guidelines have an important role in the actual clinical care of adults with CHD. However,
large outcome studies are needed to develop more precise guidelines.
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Introduction
One of the central themes of the Euro Heart surveys is the
adherence to guidelines in day-to-day clinical decision-
making. To assess the role in clinical practice of recommen-
dations based on expert consensus was an important aim of
the recently completed Euro Heart Survey on congenital
heart disease (CHD) in adults. In the relatively new ﬁeld of
adult CHD—in contrast to most other ﬁelds of cardiology—
there have hardly been any large randomized trials to vali-
date principles of management and compare treatments.
In such circumstances, guidelines may yet fulﬁl an important
role in formulating what constitutes optimal treatment, in
summarizing clinical consensus, and in structuring clinical
practice and research. In adult CHD, guidelines are
especially important for decision-making and proper timing
of (re-)intervention, for determining the optimal diagnostic
modality and frequency for patient follow-up, and for the
prescription of (prophylactic) medication. If it is found
that guidelines are not adhered to in actual practice, it
means that either education of practitioners needs to be
improved, or that the guidelines themselves are deﬁcient
and need to be adapted.
Two major sets of guidelines have recently been published
in the ﬁeld: the Canadian Cardiovascular Society/American
College of Cardiology guidelines1–4 and the guidelines of the
European Society of Cardiology.5 In this report, we describe
the adherence to guidelines as it appeared from the data
that were collected as part of the European adults CHD survey.
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Methods
The general methods followed in collecting the data for this survey
have been described previously.6 Brieﬂy, the patient population con-
sisted of patients older than 17 years of age who had one of the fol-
lowing congenital cardiac conditions (referred to as ‘defects’ in the
following): atrial septal defect II (ASD), ventricular septal defect
(VSD), tetralogy of Fallot (ToF), complete transposition of the
great arteries (TGA), aortic coarctation (CoA), Marfan syndrome,
Fontan circulation, or cyanotic disease. Consecutive patients fulﬁll-
ing the inclusion criteria (see below) were included retrospectively
at their ﬁrst visit to the outpatient clinic in 1998 (or else 1999 or
2000), and their follow-up data until December 31, 2003, were
recorded reviewing the medical chart. The database was opened
for data entry on July 1, 2003, and closed on April 30, 2004. Data
were derived from the patient ﬁles by trained nurses or physicians
and then entered into an electronic case record ﬁle (CRF). Data
collected included clinical characteristics, diagnostics and interven-
tions performed. Any signiﬁcant changes in the clinical condition
that occurred during follow-up were recorded. Separate sections
were devoted to interventional procedures, requiring both details
regarding previous interventions, and those performed during the
follow-up period.
Adherence to guidelines was evaluated for three separate
categories of guidelines: guidelines for diagnostic procedures,
operative- and catheter-based interventions, and drug treatment.
Guidelines to be chosen for analysis was determined by the follow-
ing criteria: relevance to clinical decision-making; relative simpli-
city; and ﬁtness of the required data for CRF-based evaluation. An
overview of the evaluated guidelines is shown in Tables 1–3. In
order to assess adherence to these guidelines, the patients for
whom the guidelines were relevant were selected from the data-
base. Next, the cases of these patients were entered into an analy-
sis that we shall describe separately for the different categories of
guidelines.
Diagnostic investigations
Coronary angiography prior to surgery
All patients who underwent surgery were selected from the data-
base and classiﬁed according to two criteria: whether or not
Table 1 Overview of evaluated guidelines on diagnostic
investigations
Coronary angiography prior to surgery
Marfan patients .50 years of age
Other patients .40 years of age
Imaging of the thoracic aorta in repaired aortic coarctation
Diagnostic work-up should include imaging of the aorta by MRI,
DSA, or angiography
Exercise testing in aortic coarctation
Diagnostic work-up should include exercise testing
Imaging of the abdominal aorta in Marfan patients
During follow-up, the entire aorta should be regularly evaluated
with echocardiography, MRI, CT, and/or abdominal echo
Table 2 Overview of evaluated guidelines on interventions
ASD closure
A ‘signiﬁcant’ ASD warrants intervention
A ‘signiﬁcant’ ASD:
causes volume or pressure overload (i.e. moderate/severe RV overload, PAP .35 mmHg, or LR shunt .1.5:1)
may cause exercise limitation (NYHA class .I)
may cause atrial arrhythmias
may cause paradoxical embolism
VSD closure
The following conditions may warrant VSD closure:
The presence of a ‘signiﬁcant’ VSD (i.e. moderate/severe LV overload, or PAP .50 mmHg, or LR shunt .2:1, or NYHA class .I)
The presence of a ‘signiﬁcant’ RVOT obstruction (i.e. gradient .50 mmHg, or judged to be moderate/severe)
The presence of a perimembranous VSD with moderate/severe aortic regurgitation
The presence of a subaortic VSD in combination with aortic valve prolapse
A history of endocarditis
Pulmonary valve replacement in Fallot
The presence of severe pulmonary regurgitation may warrant pulmonary valve replacement if it goes together with one of the following:
Progressive RV enlargement
Progressive tricuspid valvular regurgitation
NYHA class. I due to the defect
Arrhythmias
(Re-)coarctectomy in aortic coarctation
Presence of a ‘signiﬁcant’ (re-) coarctation may warrant intervention. A ‘signiﬁcant’ re-coarctation gives rise to hypertension (140/90),
plus one of the following:
‘pull-back’ gradient .20 mmHg; an arm-leg gradient .30 mmHg
Aortic root replacement in Marfan patients
The following situations warrant aortic root replacement:
Aortic root diameter .55 mmHg
Aortic root diameter .50 mmHg, plus:
Family history dissections, or
Growth rate .2 mm/year, or
Severe mitral or aortic valvular regurgitation
Aortic root diameter .45 mm in case valve-sparing surgery is planned
Aortic root dissection
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coronary angiography was performed, and whether or not they met
the (age) criteria speciﬁed in the guideline. This led to four possibi-
lities, two of which were classiﬁed as undue-, respectively, insufﬁ-
cient use of diagnostic investigations. An example of this decision
process is shown in Figure 1.
Imaging of the aorta and exercise testing
As the guidelines do not specify how frequently these screening
procedures should be performed, it was determined in which per-
centages of CoA, respectively Marfan patients, these procedures
had been performed after 3, 4, and 5 years of follow-up. Imaging
was deﬁned as follows: in CoA, an investigation by either magnetic
resonance imaging, or digital subtraction angiography; in Marfan
syndrome, an investigation by either magnetic resonance imaging,
or computed tomography scan, or abdominal echography. Numbers
of patients still under follow-up after 3, 4, and 5 years are
given as counts; percentages are followed by 95% conﬁdence
intervals (CI).
Operative- and catheter-based interventions
Essentially, the guidelines for operative- and catheter-based inter-
ventions specify that a particular intervention should be performed
when one or more conditions in the status of the patient are ful-
ﬁlled. In the following, we refer to this situation as the existence
of an indication.
We ﬁrst determined to which patients the particular guideline
applied. These were, respectively, patients with an open ASD at
study entry; patients with an open VSD at study entry; all Fallot
patients; all CoA patients; Marfan patients who had not undergone
an intervention before inclusion. Next, for each of these patients
it was decided whether all data items were available that were
necessary to evaluate whether or not an indication existed and
whether or not an intervention had occurred. Patients for whom
these data were lacking or insufﬁcient were excluded from further
analysis. The remaining cases were subjected to the following
assessment.
It was determined if at one point of time during follow-up an indi-
cation existed, and whether or not the patient had undergone the
particular intervention. If the answers to these two questions
were concordant, the patient was considered to have been
treated according to the guidelines. Discordant answers could
result from either one of two possibilities that were further ana-
lysed as follows:
(i) The patients with an indication who did not undergo an inter-
vention. The ﬁles of these patients were screened by the inves-
tigators (BM, PE, EB, JT: the ‘panel’) for data that might explain
why an intervention was not mentioned in their record. This was
done ﬁrst by running through a list of reasons that were expli-
citly collected on the CRF. This included the following possibili-
ties: ‘scheduled for intervention’, ‘referred’ (the design of the
survey and anonymity requirements did not allow tracing the
fate of such patients), ‘patient refusal’, ‘lost to follow-up’,
‘deceased’, ‘high-risk’, ‘mentally retarded’, or ‘symptoms
owing to other pathology’. The remaining cases were further
evaluated according to whether one of the following situations
applied: (a) the indication criteria were met only marginally or
there were contra-indications not mentioned in the current
guideline. This could lead to the consideration that non-inter-
vention was justiﬁed after all; (b) essential data were lacking
after all (which had only become apparent after a closer scru-
tiny of the case record). The cases left over after this
‘sieving’ process were considered as having not been treated
according to the guidelines (‘insufﬁcient treatment’). After
this analysis, each case was classiﬁed as ‘explained’ (scheduled
for intervention, referred, patient refusal, symptoms due to
other pathology, high-risk, mentally retarded, or otherwise jus-
tiﬁed by panel), or ‘unexplained’; the unexplained cases
included those who had deceased or were lost to follow-up
(we considered that, in principle, we could not know whether
or not these patients had been treated properly, as their
death or being lost to follow-up could either have prevented
intervention or have been the result of non-intervention),
patients for whom data were found to be lacking after all,
and, ﬁnally, the patients who, according to this analysis, had
not been treated in accordance with the guidelines.
(ii) The patients who underwent a relevant intervention, but
without an indication. Similar to the above, a reason was
sought by the investigators that could explain the intervention.
Acceptable reasons could be that the patient suffered from the
more elusive symptoms mentioned in the guidelines as warrant-
ing, but not necessarily requiring an intervention in all cases; or
Table 3 Overview of evaluated guidelines on medication
b-blocking agents in Marfan
All patients, unless intolerable side effects
Anti-coagulants for mechanical valves
All patients with a mechanical valve should be on
anti-coagulants
Anti-thrombotics for arrhythmias in Fontan
Fontan patients with atrial arrhythmias should be
anti-coagulated long-term
Figure 1 Flow chart showing which numbers of operated patients with, respectively without, an (age-based) indication for pre-operative coronary angiography
actually underwent coronary angiography.
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the patient could have an alternative indication, not mentioned
in the speciﬁc guideline; or the intervention was combined with
another procedure. This, again, resulted in a classiﬁcation of
each of these cases as either ‘explained’ (meaning that inter-
vention was justiﬁed after all) or ‘unexplained’. Some of the
unexplained cases were judged to be unexplained as essential
data was lacking after closer scrutiny of the record. The remain-
ing cases were considered as treatment not according to the
guideline (‘undue treatment’).
The process of evaluating adherence to guidelines for interven-
tions may be visualized by referring to Figure 2, which summarizes
the results of the analyses (see Results section below).
Drug treatment
The CRF contained a section devoted to drug use at inclusion and
during follow-up. When patients were started on medication
during follow-up, entry of starting dates was requested. The
Kaplan–Meier method was used to estimate the percentages (95%
CI) of patients who were using medication at the end of the
follow-up period.
All statistical calculations were performed using the statistical
package SPSS, version 12.01.
Results
The database of the Euro Heart Survey on adult CHD con-
tains data of 4110 patients. Numbers of patients per
defect and baseline characteristics of the patients are dis-
played in Table 4. As explained earlier (Methods section),
from among these patients all patients were selected to
whom one of the assessed guidelines applied. Table 5 pro-
vides an overview of the numbers of patients selected for
each guideline as well as the proportion of those for whom
sufﬁcient data for evaluation were available.
Diagnostic investigations
Coronary angiography prior to surgery
In total, there were 608 patients who underwent an oper-
ation. However, we could not include 41 patients who under-
went coronary angiography but who reached their 40th
birthday (50th in the case of Marfan patients) during
follow-up, as it was not known whether the angiography
was performed before or after that date. Thus, 567 patients
remained for the analysis, the results of which are displayed
in Figure 1. On the basis of these ﬁndings, the group of oper-
ated patients with an indication for coronary angiography
but who did not undergo angiography was compared with
the group with an indication who did undergo angiography.
Disregarding the Marfan patients, the patients who did not
undergo angiography were signiﬁcantly younger than
patients who did [median 46 years (inter-quartile range:
43–57) vs. 53 (47–62) years; P , 0.001, as assessed by the
Mann–Whitney test].
Table 4 Baseline characteristics of all patients
Inclusion
(n)
Agea Females
(%)
Atrial septal defect II 882 39 (25–52) 67
Ventricular septal defect 628 27 (20–36) 53
Tetralogy of Fallot 811 26 (21–34) 48
Aortic coarctation 551 26 (21–35) 39
Transposition great arteries 363 23 (20–27) 39
Marfan syndrome 287 29 (22–38) 50
Fontan circulation 198 23 (19–28) 45
Cyanotic defect 390 29 (23–37) 62
Overall 4110 27 (23–37) 52
aFigures represent medians (inter-quartile range).
Figure 2 Flow chart showing both the method used and the results obtained in assessing adherence to guidelines for surgical or catheter-based interventions:
ASD closure, VSD closure, pulmonary valve replacement in ToF, (re-)coarctectomy in CoA, and aortic root replacement in Marfan syndrome).
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Imaging of thoracic aorta/exercise testing in CoA
The results for the guidelines on imaging of the thoracic
aorta and exercise testing in the patients with CoA, as
well as the numbers of patients with at least 3, 4, and 5
years of follow-up respectively, are given in Table 6.
Imaging of the abdominal aorta in Marfan
Likewise, provided in Table 6 are the proportions of patients
who had undergone imaging of the abdominal aorta at 3, 4,
and 5 years respectively, as well as the number of patients
still under follow-up at these times.
Surgical- and catheter-based interventions
The aggregate results of the analyses as described in the
Methods section is shown in Figure 2. For each guideline sep-
arately, Table 7 gives the number of patients with an indi-
cation, followed by the number of cases of ‘undue
treatment’, respectively ‘insufﬁcient treatment’. Overall,
31 of the 698 patients with an indication were considered
to have been treated insufﬁciently, i.e. 4% (95% CI 3–6%);
and 15 of the 1210 patients without an indication had an
unwarranted intervention, i.e. 1% (1–2%).
Please note that in the Discussion section some details on
individual cases are mentioned. These serve the purpose of
illustrating some issues in the interpretation and functioning
of guidelines, and are not spelled out here.
Drug treatment
b-blocking agents in Marfan
Results regarding b-blocking agents in Marfan syndrome,
anti-coagulants for mechanical valves (136 patients with a
mechanical valve were identiﬁed) and anti-thrombotic
therapy for arrhythmias in Fontan are given in Table 8.
Discussion
Even though the care for adult CHD patients is a young dis-
cipline, guidelines have an important role in structuring
clinical practice. The results of the analyses presented
here conﬁrm that the actual adherence to the proposed
standards in clinical care is good with regard to the surgical-
and catheter-based interventions and the prescription of
prophylactic drugs, but not quite up to targets in the case
of diagnostic investigations. As far as surgical- and cath-
eter-based interventions are concerned, adherence to
guidelines is particularly good to relatively simple and
well-researched clinical guidelines, namely aortic root
replacement in the Marfan syndrome, and ASD and VSD
closure.
The method that was used to assess adherence to guide-
lines was to ‘ﬁlter out’ the patients who were not treated
strictly according to the guidelines, and to subject these
cases to a further scrutiny of the patient ﬁle for additional
clinical information that could explain apparent deviation
from the guideline. The logic behind this last step in the
sieving process was the assumption that there is a ‘grey
area’ in which the guideline is not decisive. In this discus-
sion, particular attention will be devoted to these border-
line cases, as they are the most instructive in evaluating
the appropriateness of the current guidelines.
Diagnostic investigations
Most adult CHD patients are under regular follow-up.
Screening and monitoring therefore are key elements in
optimizing care.
Pre-operative coronary angiography is indicated in older
patients to exclude coronary artery disease that might com-
plicate the peri-operative course. We found that almost half
of the patients above 40 years of age (50 in the case of the
Marfan syndrome, because of the risk of compromising the
fragile aortic root) did not undergo coronary angiography
before surgery. The fact that the mean age was signiﬁcantly
lower in the patients who did not undergo angiography
seems to indicate that in practice a higher age limit is
observed. It should be noted that the prevalence of coronary
artery disease as diagnosed by coronary angiography is
below 4% for asymptomatic patients aged 40–70 years7 and
does not seem to increase sharply between 40 and 50
years of age. The evidential basis for a lower limit of an
age of 40 as criterion for performing coronary angiography
is rather weak. Therefore, this guideline might be a candi-
date for revision.
The other diagnostic procedures assessed pose a problem
of a somewhat different nature. All pertain to screening and
monitoring, i.e. serial measurements. Yet, the guidelines
are silent as to how frequently investigations should be
done. We have therefore considered periods of follow-up
of 3, 4, and 5 years, assuming that the aortic diameters
should be determined at least once in every 5 years. The
fact that we found hardly any differences between follow-
up of 3 and 5 years suggests that either aortic diameters
are being monitored at regular time-intervals of at most a
few years, or that they are monitored infrequently, or not
at all. In any case, the outcome of our analysis should be
Table 5 Patients included per guideline assessed
Diagnostics n/ma Interventions n/m Drug treatment n/m
Imaging thoracic aorta in CoA 551/551 Closure of ASD 495/504 b-blockers in Marfan 287/287
Exercise testing in CoA 551/551 Closure of VSD 247/352 Anti-coagulants for
mechanical valves
316/316
Imaging abdominal aorta in Marfan 286/287 PVR in Tetralogy of Fallot 547/811 Anti-thrombotics for
arrhythmias in Fontan
117/117
Coronary angiography prior to surgery 567/608 (Re-)coarctectomy in CoA 411/551
ARR in the Marfan syndrome 208/211
PVR, pulmonary valve replacement; ARR, aortic root replacement.
aThe ﬁgures represent the total number of patients to which the guideline applied (m) and the number of patients with sufﬁcient data for analysis (n).
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the cause for concern that this guideline is insufﬁciently put
into practice. As availability of imaging equipment is still
limited, no distinction was made regarding the mode of
imaging. However, it is to be expected that future research
results will favour particular forms of imaging.
Surgical- and catheter-based interventions
In contrast to most other congenital heart defects, ASDs
often manifest themselves for the ﬁrst time in adulthood.
In most specialized centres, the evaluation of open ASDs in
adults is an important part of their care. The relatively
long clinical experience with the management of ASDs has
led to guidelines that are quite clear and well supported.
Surgical repair of ASDs in childhood is known to be associ-
ated with excellent outcomes.8 Because now almost all
ASDs discovered in childhood are closed, we may assume
that in most cases of an open ASD in our database the
defect had remained undiscovered during childhood.
The risks and beneﬁts of closure later in life have been
the subject of debate. In only one prospective randomized
study, surgical treatment was compared with medical treat-
ment in adults.9 Despite the lack of hard evidence, the
results of several retrospective follow-up studies9–12 have
led to the almost uniform consensus that a ‘signiﬁcant’
ASD when it becomes manifest in adulthood should be
closed. Our analysis seems to conﬁrm that the guideline is
closely adhered to. However, the precise conditions favour-
ing closure vs. conservative treatment have not been clearly
deﬁned. Moreover, closure of ASDs by a catheter-based
technique appears to be associated with fewer/less severe
complications in older patients, although long-term follow-
up is not yet available. Hence, this current trend might
necessitate a revision of the guideline.
In our cohort, a shunt with a Qp:Qs ratio. 1.5:1 and/or
pulmonary hypertension were major indications for treat-
ment. It should be noted, however, that a cut-off of 1.5:1
for the shunt ratio is not always observed in the literature.
Thus, Attie et al.9 used a ratio greater than 1.7:1, estab-
lished by right heart catheterization, as an inclusion cri-
terion for their study.
Apart from these haemodynamic criteria, the guidelines
mention a history of arrhythmias and/or paradoxical embo-
lism as possible indications for ASD closure. However, it has
been shown that ASD closure is not an effective remedy for
arrhythmias.10,11 In our cohort, there were two patients
with atrial arrhythmias as the sole reason for ASD closure.
In addition, there were seven patients in whom paradoxical
embolism was the sole reason for closure.
Compared with ASDs, only few VSDs needed to be closed
[36 of 352 unclosed VSDs (10%), compared with 296 of 504
unclosed ASDs (59%)], which is not surprising given the fact
that most VSDs are discovered in childhood. It is known
that the long-term outcome is good after VSD closure in
Table 6 Diagnostic investigations
Aortic coarctation Marfan
X-ECG (n ¼ 551) Imaging thoracic aorta (n ¼ 551) Imaging abdominal aorta (n ¼ 286)
3 years follow-up n ¼ 478 52% (47–56) n ¼ 478 54% (50–58) n ¼ 261 66% (60–71)
4 years follow-up n ¼ 405 53% (48–58) n ¼ 405 55% (50–59) n ¼ 223 70% (64–76)
5 years follow-up n ¼ 325 52% (47–57) n ¼ 325 55% (49–60) n ¼ 182 73% (66–79)
Figures represent percentages (95% conﬁdence interval) preceded by the number of patients with 3, 4, and 5 years of follow-up, respectively.
Table 7 Adherence to the guidelines for surgical/catheter-based interventions
No. of patients with
indication
Cases of undue
treatment
Cases of insufﬁcient
treatment
Closure of ASD 434 /495 1 3
Closure of VSD 80 /247 1 1
PVR in Tetralogy of Fallot 65 /547 5 10
(Re-)coarctectomy in CoA 86 /411 6 14
ARR in the Marfan syndrome 33 /208 2 3
Overall 698 /1902 15 (1%)a 31 (4%)b
PVR, pulmonary valve replacement: ARR, aortic root replacement.
Figures represent counts. The denominators in the ﬁrst column represent the number of patients to whom the
guideline applies and for whom sufﬁcient data was available.
aExpressed as percentage of patients without an indication (95% conﬁdence interval: 1–2%).
bExpressed as percentage of patients with an indication (95% conﬁdence interval 3–6%).
Table 8 Prophylactic medication
Using mediationa (%)
b-blockers in Marfan 76 (71–82)
Anti-coagulants for mechanical valves 95 (91–99)
Anti-thrombotics for arrhythmias in Fontan 91 (83–99)
aFigures refer to the percentages of patients (95% conﬁdence interval)
using medication at baseline or started at some time during follow-up, as
estimated with the Kaplan–Meier method.
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infancy and childhood.13 On the other hand, an unclosed sig-
niﬁcant defect may lead to substantial pathology later in life,
in particular pulmonary hypertension and left ventricle over-
load. We found no patients who should certainly have been
operated but who were not. There were, however, several
cases that give food for thought. In particular, the role of a
history of endocarditis is unclear. In three cases, this was
the only reason for operating, while on the other hand 12
unoperated patients had a history of endocarditis. There
also is the question whether patients with only one of the
indications for intervention should always be treated accord-
ingly. For example, two patients had only moderate left ven-
tricular volume overload, and two patients were in NYHA
functional class II due to the VSD, but did not qualify for
any of the other criteria. On the other side of the spectrum,
a patient should be mentioned who was in NYHA class IV and
had a left ventricular ejection fraction of 31%, but was not
operated. Would this patient have beneﬁted from closure
of the VSD, or would an operation have further compromised
the left ventricular function and provoked heart failure? In
other words: should the guideline specify when the risks of
operation outweigh the beneﬁts?
Probably, the least well-established guideline is that for
pulmonary valve replacement after correction of the ToF.
After corrective repair of Fallot, re-intervention was necess-
ary in about 10% of patients over a 20-year follow-up
period.14 In most cases, the intervention concerned the
right ventricular outﬂow tract. One recent study reported
that in a population of 171 patients with a mean follow-up
of approximately 10 years, 9% of the patients underwent
pulmonary valve repair.15 Some degree of pulmonary valve
insufﬁciency develops in almost all patients. It is generally
agreed that in the more severe forms of pulmonary regurgi-
tation, pulmonary valve replacement is indicated. However,
the timing of the intervention is still an important matter of
debate and research.16,17 Therefore, it must be concluded
that the indications as set forth in this guideline are
subject to alternative interpretation and are likely to be
revised as more outcome data become available. Not sur-
prisingly, we found more departures from this guideline
than from those in the other cases. Deviations may be cate-
gorized as follows. First, in several cases pulmonary stenosis
and not pulmonary insufﬁciency was the probable reason for
pulmonary valve replacement. In other cases, moderate
(and not severe) pulmonary regurgitation occurred in combi-
nation with one of the other criteria. This reﬂects the fact
that it may be difﬁcult to quantify the severity of PI. In
one case, moderate PI in combination with a right ventricu-
lar outﬂow tract aneurysm (not mentioned in the guideline)
probably was the reason for intervention. But even after
classifying all these cases as ‘acceptable’, 15 cases
remained in which treatment was incorrect, according to
our appraisal (10 cases of ‘insufﬁcient treatment’ and ﬁve
cases of ‘undue treatment’).
Compared with the guidelines discussed earlier, which
pertain to often complex clinical decision-making, the guide-
line for aortic root replacement in Marfan is rather straight-
forward and provides clear-cut criteria that can be readily
established. The observation that dissection/rupture of the
aorta in Marfan syndrome is in many cases preceded by a
widening of the aortic root, has led to the strategy of prophy-
lactic replacement of the aortic root. Cut-off values have
been proposed and found to be satisfactory.18 We found
only three cases in which aortic root replacement was not
performed when it should have been, and two cases in
which it was performed while the aortic root diameter was
below the threshold. A further indication for the impact of
this guideline is the fact that in most cases aortic root diam-
eters were available. Yet, it should be noted that when aortic
root regurgitation is present, it may be a reason to replace
the aortic root earlier (a few cases in our database). Also,
improvements of surgical techniques, in particular valve-
sparing techniques, may shift the beneﬁt/risk ratio and
provide a rationale for earlier intervention.
The guideline for (re-)coarctectomy likewise relates to
monitoring of aortic dimensions. After repair of CoA,
residual or re-stenosis at the site of repair often necessi-
tates a repeat intervention,19 while untreated patients
with (mild) CoA may become symptomatic later in life. The
main reason to intervene in these cases is to attenuate the
deleterious effects of the systemic arterial hypertension
that goes with coarctation. These are such that, except in
the case of very mild obstructions, interventions are
indicated. The crucial haemodynamic feature that is used
for diagnostic and monitoring purposes is the difference in
blood pressure in the upper and the lower part of the
body. This can be determined invasively by catheter.
However, invasive diagnostics have been largely replaced
by non-invasive imaging modalities, in particular Doppler
echocardiography (‘sawtooth’ phenomenon) and magnetic
resonance imaging. Unfortunately, these methods do not
directly assess the haemodynamic severity of the stenosis.
The requirement of the presence of ‘resting or exercise-
induced hypertension and a resting arm/leg blood pressure
gradient .30 mmHg’ is therefore a criterion that is, in a
sense, a compromise.
Judging from our data, actual treatment tends to be more
conservative than recommended in this guideline. We found
16 cases in which the intervention criteria were fulﬁlled but
in which no intervention took place, vs. ﬁve cases in which
an unwarranted intervention was performed. In one of
these cases the criterion for intervention was the ratio of
aortic diameter at the stenosis site over the diameter at
the diaphragmatic level (,0.7), which is an accepted cri-
terion. It should further be noted that the untreated cases
might include patients who were inoperable for anatomical
reasons (hypoplastic arch).
This tendency towards a more conservative approach is
especially noteworthy given the fact that recent research
ﬁndings indicate that treatment should be even more
aggressive than as recommended by the current guideline,
in particular, as the advent of transcatheter techniques
will reduce interventional risks.20
Medication
In general, the repertoire of drugs used in adult CHD is not
different from that in other ﬁelds of cardiology. However,
the indications for prescribing medication may be different.
One example is the prophylactic prescription of b-blockers
to prevent aortic dissection in Marfan patients.21 The fact
that more than 70% of the Marfan patients in the database
were using b-blockers shows that this guideline is fairly
well established, considering that the existence of side
effects and patient reluctance to use b-blockers render
the target of 100% unrealistic.
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The use of anti-thrombotics after mechanical valve
implantation is a general principle in cardiology.22 Our
ﬁnding that almost 10% of patients in this category were
not using any form of anti-coagulation is therefore slightly
alarming.
Prevention of thrombo-embolic events is also necessary in
patients with Fontan circulation when they suffer from
arrhythmias. As the prevalence of supraventricular arrhyth-
mias is very high, this concerns a large proportion of the
Fontan patients. Unfortunately, the Fontan circulation may
also disturb the coagulation proﬁle in such a manner that
bleeding disorders result.23 Anti-coagulation management
in Fontan patients therefore, remains a major challenge
that future guidelines will need to address.
Limitations
Evaluation of the adherence to guidelines in this survey did
not have the character of an ‘audit’ and cannot be con-
sidered as an assessment of the ‘quality of care’.
Participation was on a voluntary basis, and data-entry was
done by the participants in this survey, who, in many
cases, included their own patients, with no hard guarantee
of accuracy and reliability. Moreover, we based our assess-
ment on data that were collected by means of a standar-
dized electronic CRF. This imposed limits on the amount of
detail with which we could evaluate each case. In particular,
we were not able to include the full process of clinical
decision-making with all its subtleties. On the one hand,
we were not able to further analyse patients who were
lost to follow-up, were referred to another centre, or
died. On the other hand, we were not able to give the treat-
ing cardiologist a ‘fair hearing’ in case of apparent non-
adherence to a guideline.
Conclusion
This survey shows that guidelines have gained an important
role in the care for adult patients with CHD. Actual adher-
ence to the proposed standards was found to be generally
good, although in some aspects of clinical care, in particular
the performance of diagnostic investigations at regular
intervals, there was a lack of compliance, which is a cause
for concern. As guidelines mostly incorporate previously
established rules of good practice, also in a young discipline
such as adult CHD treatment, recommendations should be
formulated and offered to physicians working in the ﬁeld,
to encourage and support them in providing optimized
care to their patients. Despite their possible need for revi-
sion and improvement, they seem to provide a practical
and effective way to promote and consolidate good prac-
tice. In addition, they might be used as the basis for
reﬁned clinical research.
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Organization of the survey
Expert Committee: Barbara Mulder (Survey chairperson), the
Netherlands; Eric Boersma, the Netherlands; Luciano Daliento,
Italy; Michael Gatzoulis, UK; Rafael Hirsch, Israel; Harald
Kaemmerer, Germany; Folkert Meijboom, the Netherlands; Philip
Moons, Belgium; Erwin Oechslin, Switzerland; Jana Popelova´,
Czech Republic; Erik Thaulow, Norway; Ulf Thile´n, Sweden; Jan
Tijssen, The Netherlands.
Coordination and Data Management Centre (Euro Heart House,
Sophia-Antipolis, France):
KeithMcGregor (ESC Scientiﬁc Director); Malika Manini (EHS
Operations Manager); Charles Taylor (EHS Database administrator);
Claire Bramley, Vale´rie Laforest (EHS Data Monitors); Susan Del
Gaiso (EHS Assistant).
Data Analysis Centre (Cardiology Department, Academic Medical
Centre, Amsterdam, the Netherlands): Peter Engelfriet, Jan Tijssen.
National Coordinators: Belgium, Guy De Backer; Switzerland,
Peter Buser; Czech Republic, Roman Cerbak; Germany, Uwe
Zeymer; Denmark, Per Thayssen; Spain, Angeles Alonso; Finland,
Seppo Lehto; France, Jean-Jacques Blanc; UK, Kevin Fox; Greece,
Dennis Cokkinos; Hungary, Kristof Karlocai; Israel, Sholmo Behar;
Italy, Aldo Maggioni; Lithuania, Virginija Grabauskiene; the
Netherlands, Jaap W. Deckers; Poland, Janina Stepinska; Russia,
Vyacheslav Mareev; Sweden, Annika Rosengren; Turkey, Tugrul Okay.
There was no national coordinator in the participating countries,
which are not mentioned in the above list.
Sponsors: European Society of Cardiology; Dutch Heart
Foundation.
Participating Centres and Investigators with numbers of patients
included per country:
Armenia (60): Karine Sargsyan, Yerevan. Austria (94): Harald
Gabriel, Vienna; B. Simma, Michael Fritz, Feldkirch. Belgium
(170): Werner Budts, Kristien Van Deyk, Philip Moons, Leuven;
Julie De Backer, Daniel De Wolf, Johan De Sutter, Bert Suys,
Ghent; Martial Massin, Liege; Agnes Pasquet, Marielle Morissens,
Brussels; Czech Republic (123): Jana Popelova, Ingrid Majerova,
Prague; Jindrich Spinar, Anna Necasova, Tomas Brychta, Tomas
Zatocil, Brno; Egypt (20): Nader Botros, Hala El Farghaly, Ahmed
El Maghrabi, Giza; Galal El Said, Sherif El Tobgi, Khalid Sorour,
Zeinab Ashour, Howaida G. El Said, Wael Abdelaal, Ali Amer Zakia,
Amir Abdulwahab, Khalid Tammam, Cairo; Estonia (3): Imbrit
Loogna, Tallinn. France (46): Laurence Iserin, Paris; Guillaume
Jondeau, Boulogne-Billancourt; Yvette Bernard, Besanc¸on.
Germany (208): Gu¨nther Breithardt, Jorge Oberfeld, Thomas
Wichter, Stefan Gunia, Muenster; John Hess, Harald Kaemmerer,
Annette Wacker, Munich; Reinald Motz, Oldenburg; Peter Lange,
Ulrike Bauer, Berlin; Walter Hoffmann, Sabine Nusser, Homburg/
Saar. Greece (88): Spyridon Rammos, Eftihia Smparouni, Pipina
Bonou, Stella Brili, Athens; Periklis Davlouros, Patras; Christos
Ntellos, Piraeus. Hungary (93): Andras Temesvari, Olga Suranyi,
Budapest; Tamas Forster, Marta Hogye, Szeged. Israel (234):
Rafael Hirsch, Petach Tikva. Italy (329): Davide Pacini, Nicola
Camurri, Bologna; Luciano Daliento, Padua; Roberto Crepaz,
Roberto Cemin, Bolzano. Lithuania (99): Alicija Dranenkiene, Lina
Gumbiene, Vilnius. Macedonia (73): Elizabeta Srbinovska
Kostovska, Skopje. the Netherlands (706): Chris Jansen,
F.J. Meijboom, J.W. Roos-Hesselink, Rotterdam; Harry Crijns,
Heidi Fransen, Maastricht; Barbara Mulder, Tanja Megens, Peter
Engelfriet, Amsterdam; Arie van Dijk, Colinda Koppelaar,
Nijmegen; Hubert Vliegen, Tanja Megens, Leiden; Tieneke Ansink,
Lelystad; Dirk Jan van Veldhuisen, T. Steenhuis, Henriette Tebbe,
Groningen; Jan Hoorntje, Henriette Tebbe, Annette M. Bootsma,
Zwolle; J.B. Winter, H.M.P. Broers, Tilburg; C. Werter, Adrie van
den Dool, Roermond; Norway (75): Erik Thaulow, J. Westby,
Thomas Moller, Oslo; Poland (187): Piotr Hoffman, Anna Klisiewicz,
Warszawa; Marianna Janion, Marcin Sadowski, Kielce; Olga
Trojnarska, Poznan; Tracz Wieslawa, Piotr Podolec, Elzbieta
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Suchon, Monika Pieculewicz, Jerzy Sadowski, Krakow; Jan Erecinski,
Joanna Kwiatkowska, Gdansk; Jacek Bialkowski, Helena
Zakliczynska, Zabrze. Portugal (188): Maria Celeste Vagueiro,
Claudio Vergulio Antunes David, Lidia de Sousa, Lisbon; Maria da
Grac¸a Castro, Coimbra; Vasco Gama Ribeiro, Conceicao Fonseca,
V.N. Gaia; Cristina Cruz, Porto. Romania (90): Ioan Mircea Coman,
Alexandra Gherghina, Mihaela Marin, Bucharest. Slovakia (11):
Pavol Kunovsky, Viera Vrsanska, Bratislava. Slovenia (75): Peter
Rakovec, Mirta Kozelj, Katja Prokselj, Ljubljana. Spain (317):
Jaume Casaldaliga, Joan Cinca, Maite Subirana Domenech,
Barcelona; Jose Juan Gomez de Diego, Jose Maria Oliver, Marta
Mateos, Madrid; Roberto Barriales-Villa, Pontevedra; Maria Jose
Rodriguez Puras, Sevilla. Sweden (249): Ulf Naslund, Karin Olsson,
Umea; Peter Eriksson, Hrodmar Helgason, M. Dellborg,
Gothenburg; Gunilla Forssell, Katarina Ogenholt, Stockholm; Ulf
Thile´n, Lund. Switzerland (309): Peter Eichhron, Schwyz; Heinz
Schlapfer, Biel/Bienne; Markus Schwerzmann, Bern; Erwin
Oechslin, Zurich; Matthias Pﬁsterer, Andreas Hoffmann, Basel.
Turkey (2): Haldun Muderrisoglu, Mehmet E. Korkmaz, Vahide
Pimpek, Ankara. UK (261): Graham Stuart, Lisa Curthoys, Bristol;
G.Y.H. Lip, T. Millane, Deirdre Lane, Ben Sutton, Sara Thorne,
Patrick Disney, Birmingham; Michael Gatzoulis, Beatriz Bouzas
Zubeldia, London.
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